SERA vs. FLGT, CSTL, PSNL, INNV, EHAB, SBC, CELC, AUNA, TALK, and OMDA
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), InnovAge (INNV), Enhabit (EHAB), SBC Medical Group (SBC), Celcuity (CELC), Auna (AUNA), Talkspace (TALK), and Omada Health (OMDA). These companies are all part of the "healthcare" industry.
Sera Prognostics vs. Its Competitors
Fulgent Genetics (NASDAQ:FLGT) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
Fulgent Genetics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
Sera Prognostics has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fulgent Genetics had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Fulgent Genetics and 2 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.72 beat Fulgent Genetics' score of 0.23 indicating that Sera Prognostics is being referred to more favorably in the news media.
Fulgent Genetics presently has a consensus target price of $24.00, indicating a potential upside of 19.64%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Fulgent Genetics is more favorable than Sera Prognostics.
48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Comparatively, 13.5% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Fulgent Genetics has a net margin of -13.94% compared to Sera Prognostics' net margin of -28,685.22%. Fulgent Genetics' return on equity of -2.19% beat Sera Prognostics' return on equity.
Summary
Fulgent Genetics beats Sera Prognostics on 10 of the 16 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
This page (NASDAQ:SERA) was last updated on 7/4/2025 by MarketBeat.com Staff
